Investigational drug · Phase 2
CAP256V2LS
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HIV-1-infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "CAP256V2LS"
First trial start
2022
Jun 9, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CAP256V2LS", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV-1-infection
Approved drugs for the same conditions: HIV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "CAP256V2LS" as an intervention, largest first.
- A Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV- Negative WomenPivotal-lookingCompleted
Centre for Infectious Disease Research in ZambiaAcademic, hospital or other
NCT07810062 · 990 participants · Start Aug 28, 2023 · Primary completion Jun 30, 2024
Drug: Broad band monoclonal antibodies named as CAP256V2LS and VRC07- 523LS · For: To Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS Monoclonal Antibodies in HIV-negative Women
Sites: Lusaka, Zambia
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT06585891 · 24 participants · Start Oct 7, 2024 · Primary completion Sep 30, 2025
Drug: VRC-HIVMAB0121-00-AB · For: HIV Infection
Sites: Bethesda, Maryland
Gilead SciencesGilead Sciences (GILD)
NCT05281510 · 20 participants · Start Jun 9, 2022 · Primary completion Jan 16, 2025
Drug: Vesatolimod; VRC07523LS and 1 more · For: HIV-1-infection
Sites: Umlazi, South Africa
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT04408963 · 10 participants · Start Mar 22, 2022 · Primary completion Nov 28, 2022
Drug: VRC-HIVMAB0102-00-AB · For: HIV
Sites: Bethesda, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Cervicovaginal microbiome diversity was not associated with mucosal pharmacokinetics of systemically delivered HIV broadly neutralizing antibodies.
Mtshali A, Togo AH, Kama A, et al. · Sci Rep 2026
- Monitoring broadly neutralising HIV antibody concentrations using microsampling on dried blood spots in infants.
Latour R, Mkhize NN, Debiesse S, et al. · J Infect 2026
- Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody.
Mahomed S, Mkhize NN, Serebryannyy LA, et al. · medRxiv 2025
- Hyaluronidase-enhanced subcutaneous delivery of bNAbs: a phase 1 randomized controlled clinical trial in HIV-uninfected women.
Mahomed S, Osman F, Beliveau M, et al. · Nat Commun 2025
- Population pharmacokinetics of weight-based compared with fixed dosing of CAP256V2LS, a broadly neutralizing antibody for HIV prevention in women.
Mahomed S, Beliveau M, Heredia-Ortiz R, et al. · J Antimicrob Chemother 2025
- Safety and pharmacokinetics of subcutaneous administration of broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed, uninfected neonates and infants: study protocol for a phase I trial.
Goga A, Ramraj T, Naidoo L, et al. · BMC Infect Dis 2024
Also in development for HIV-1-infection
- GS-3242Phase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- LEN FDCPhase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- OBRPhase 32 trials
Gilead Sciences · HIV-1-infection
- TMB-365TMB-380, VRC07523LSPhase 23 trials
TaiMed Biologics Inc. · HIV-1-infection, HIV -1 Infection
- PirmitegravirPhase 21 trial
ST Pharm Co., Ltd. · HIV-1-infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.